{"id":2203,"date":"2025-10-22T14:45:49","date_gmt":"2025-10-22T18:45:49","guid":{"rendered":"https:\/\/old.karikarilab.org\/?p=2203"},"modified":"2025-10-22T16:24:27","modified_gmt":"2025-10-22T20:24:27","slug":"dr-thomas-k-karikari-and-the-biofluid-biomarker-lab-participate-in-the-argonaut-club-voyager-summit-2025","status":"publish","type":"post","link":"https:\/\/old.karikarilab.org\/?p=2203","title":{"rendered":"Dr. Thomas K. Karikari and the Biofluid Biomarker Lab Participate in the ARGOnaut Club Voyager Summit 2025"},"content":{"rendered":"\n<h5 class=\"wp-block-heading\"><strong>By Happiness E. Aigbogun | Karikari Lab<\/strong><\/h5>\n\n\n\n<p>From <strong>October 13\u201315, 2025<\/strong>, leading scientists, clinicians, and biotechnology innovators who were early adopters of the ARGO HT platform from Alamar Biosciences convened in Napa, California, for the inaugural <strong>ARGOnaut Club Voyager Summit 2025<\/strong> &#8211; an annual event dedicated to advancing biomarker science and translational innovation in healthcare.<\/p>\n\n\n\n<p>Representing the <strong>Biofluid Biomarker Lab (Karikari Lab)<\/strong> at the <strong>University of Pittsburgh<\/strong>, <strong>Dr. Thomas K. Karikari, PhD<\/strong>, served as one of the distinguished keynote speakers. As <strong>Director and Principal Investigator<\/strong> of the Karikari Lab, Dr. Karikari delivered an engaging presentation on <strong>biofluid biomarkers for neurodegenerative diseases<\/strong>, focusing on developing precise and accessible tools for diagnosing and monitoring Alzheimer\u2019s disease.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cOur goal,\u201d Dr. Karikari explained, \u201cis to bridge the gap between laboratory discoveries and real-world clinical applications. By developing reliable biomarkers from blood and other biofluids, we can make early diagnosis and disease tracking more accessible to patients globally.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>His keynote emphasized the lab\u2019s current research efforts, including the validation of <strong>plasma biomarkers<\/strong> that accurately reflect brain pathology, the optimization of <strong>assay performance<\/strong>, and a strong commitment to ensuring <strong>equitable diagnostic applications<\/strong> across diverse populations.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cEquity in science and healthcare is central to what we do,\u201d Dr. Karikari added. \u201cWe are working not just to create accurate tests, but to ensure they are effective across different ancestry groups, locations, and health settings. This is how we make science truly global.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>Joining Dr. Karikari at the summit were <strong>James Emanuel<\/strong> and <strong>Marissa Farinas<\/strong>, members of the Karikari Lab who actively participated in discussions and networking sessions throughout the event. Their presence highlighted the lab\u2019s collaborative spirit and its dedication to mentoring emerging scientists in biomarker research.<\/p>\n\n\n\n<p>Reflecting on her experience, <strong>Marissa Farinas<\/strong> shared valuable insights into the summit\u2019s focus and impact:<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cPresenters discussed biomarker discovery, translational and clinical research, the implementation of biomarkers in the clinic, and future directions for aging and health monitoring.\u201d said Farinas. \u201cI met with several Alamar R&amp;D scientists to not only learn about their assay development process but also to provide feedback on my experience with NULISA. It was intriguing to hear how the NULISA technology is being used in both academic and industry settings for a range of conditions, including Alzheimer\u2019s disease, Parkinson\u2019s disease, obesity, and traumatic brain injury. After attending the summit, I\u2019m inspired to explore specific protein targets in our datasets and look into unique cohorts of participants, such as presymptomatic individuals and pre-\/peri-\/post-menopausal women.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"771\" src=\"https:\/\/old.karikarilab.org\/wp-content\/uploads\/2025\/10\/PXL_20251014_153358591-1024x771.jpg\" alt=\"\" class=\"wp-image-2205\" srcset=\"https:\/\/old.karikarilab.org\/wp-content\/uploads\/2025\/10\/PXL_20251014_153358591-980x738.jpg 980w, https:\/\/old.karikarilab.org\/wp-content\/uploads\/2025\/10\/PXL_20251014_153358591-480x362.jpg 480w\" sizes=\"auto, (min-width: 0px) and (max-width: 480px) 480px, (min-width: 481px) and (max-width: 980px) 980px, (min-width: 981px) 1024px, 100vw\" \/><\/figure>\n\n\n\n<h6 class=\"wp-block-heading has-text-align-center\"><strong><sup>Dr Thomas K. Karikari giving his presentation at ARGOnaut Club Voyager Summit 2025.<\/sup><\/strong><\/h6>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cConferences like this remind us that science thrives through collaboration,\u201d noted<strong> Dr. Karikari<\/strong>. \u201cIt\u2019s not just about presenting our data, it\u2019s about learning from others, challenging assumptions, and finding shared paths toward better diagnostics and treatment strategies.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>The <strong>ARGOnaut Club Voyager Summit<\/strong> provided a dynamic platform for connecting academic researchers with biotechnology partners, fostering dialogue that drives translational breakthroughs. Discussions across the three-day meeting covered critical areas such as <strong>biomarker discovery<\/strong>, <strong>clinical validation<\/strong>, and the <strong>future of aging and health monitoring<\/strong>.<\/p>\n\n\n\n<p>The <strong>Biofluid Biomarker Lab (Karikari Lab)<\/strong> continues to play a pivotal role in advancing biomarker research for Alzheimer\u2019s disease and other neurodegenerative disorders. Its participation in this year\u2019s summit underscores the lab\u2019s leadership in the field and its dedication to scientific excellence, inclusivity, and innovation.<\/p>\n\n\n\n<p>As the summit concluded, Dr. Karikari expressed optimism about the direction of biomarker research:<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p>\u201cThe progress we\u2019ve seen in recent years is just the beginning. With continued teamwork and innovation, we\u2019re moving closer to a world where early, accurate, and accessible diagnosis of neurodegenerative diseases becomes the norm.\u201d<\/p>\n<\/blockquote>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Stay Connected<\/strong><\/h3>\n\n\n\n<p class=\"has-black-color has-text-color has-link-color wp-elements-84b440a86e241620f25bd36ab05d8c93\">Follow the Karikari Lab\u2019s ongoing research and updates:&nbsp;<\/p>\n\n\n\n<p>Website:&nbsp;<a href=\"https:\/\/old.karikarilab.org\/home-page\/\">Karikari Lab<\/a><\/p>\n\n\n\n<p id=\"ember201\">LinkedIn:&nbsp;<a href=\"https:\/\/www.linkedin.com\/company\/karikari-lab\">LinkedIn<\/a><\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><\/p>\n<\/blockquote>\n","protected":false},"excerpt":{"rendered":"<p>By Happiness E. Aigbogun | Karikari Lab From October 13\u201315, 2025, leading scientists, clinicians, and biotechnology innovators who were early adopters of the ARGO HT platform from Alamar Biosciences convened in Napa, California, for the inaugural ARGOnaut Club Voyager Summit 2025 &#8211; an annual event dedicated to advancing biomarker science and translational innovation in healthcare. [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":2204,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"off","_et_pb_old_content":"","_et_gb_content_width":"","_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[9],"tags":[],"class_list":["post-2203","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/old.karikarilab.org\/index.php?rest_route=\/wp\/v2\/posts\/2203","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/old.karikarilab.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/old.karikarilab.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/old.karikarilab.org\/index.php?rest_route=\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/old.karikarilab.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2203"}],"version-history":[{"count":3,"href":"https:\/\/old.karikarilab.org\/index.php?rest_route=\/wp\/v2\/posts\/2203\/revisions"}],"predecessor-version":[{"id":2222,"href":"https:\/\/old.karikarilab.org\/index.php?rest_route=\/wp\/v2\/posts\/2203\/revisions\/2222"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/old.karikarilab.org\/index.php?rest_route=\/wp\/v2\/media\/2204"}],"wp:attachment":[{"href":"https:\/\/old.karikarilab.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2203"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/old.karikarilab.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2203"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/old.karikarilab.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2203"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}